Bridge City Capital LLC bought a new stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,971 shares of the medical research company’s stock, valued at approximately $2,518,000. PAREXEL International Corporation accounts for 2.1% of Bridge City Capital LLC’s portfolio, making the stock its 4th largest position. Bridge City Capital LLC owned 0.06% of PAREXEL International Corporation at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PRXL. Capstone Asset Management Co. increased its stake in PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock valued at $278,000 after buying an additional 160 shares during the period. Clinton Group Inc. purchased a new stake in PAREXEL International Corporation during the first quarter valued at about $3,682,000. LSV Asset Management increased its stake in PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock valued at $24,029,000 after buying an additional 116,200 shares during the period. Macquarie Group Ltd. purchased a new stake in PAREXEL International Corporation during the fourth quarter valued at about $789,000. Finally, Gabelli Funds LLC purchased a new stake in PAREXEL International Corporation during the first quarter valued at about $1,136,000. Institutional investors and hedge funds own 91.58% of the company’s stock.

PAREXEL International Corporation (NASDAQ PRXL) traded up 0.02% on Friday, hitting $87.70. 174,583 shares of the stock traded hands. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.86. The stock has a 50-day moving average of $87.49 and a 200-day moving average of $75.19. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 38.55 and a beta of 0.79.

ILLEGAL ACTIVITY WARNING: “Bridge City Capital LLC Takes Position in PAREXEL International Corporation (PRXL)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/25/bridge-city-capital-llc-takes-position-in-parexel-international-corporation-prxl.html.

Several research firms recently issued reports on PRXL. Zacks Investment Research raised shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Saturday, August 19th. BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Jefferies Group LLC reaffirmed a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research note on Tuesday, June 20th. Finally, Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. PAREXEL International Corporation has a consensus rating of “Hold” and an average price target of $75.93.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.